INMB

INmune Bio (INMB)

About INmune Bio (INMB)

INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer’s disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.

Details

Daily high

$1.68

Daily low

$1.54

Price at open

52 Week High

$11.64

52 Week Low

$1.09

Market cap

41.2M

Dividend yield

0.00%

Volume

8,594

Avg. volume

460,163

P/E ratio

-.91

INmune Bio News